文献速递角膜与眼表疾病

聚六亚甲基双胍滴眼液的安全性:健康成人随机临床试验

Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers.
PubMed 文献 · Br J Ophthalmol · 2020-11-25

该前瞻性随机双盲对照试验在90名健康志愿者中评估了0.04%、0.06%、0.08%聚六亚甲基双胍(PHMB)滴眼液与安慰剂的安全性。结果显示,剂量限制性不良事件仅见于0.06%和0.08%组共5例,无显著组间差异;0.08%组角膜点状着色更常见但可完全恢复。结论认为0.02% PHMB使用者可安心,0.08%在治疗试验中具有合理性。

要点

  • 0.06%和0.08% PHMB组共5例出现剂量限制性不良事件,均自行恢复。
  • 0.08% PHMB组角膜点状着色更常见,但7-14天内完全消退。
  • 除0.08%组角膜点状着色外,未观察到不良事件随浓度增加的趋势。

核心结论

  • 研究结果对使用0.02% PHMB的患者具有安抚意义。
  • 较高浓度PHMB在棘阿米巴角膜炎受试者中可能具有可接受的耐受性和毒性水平。
  • 鉴于较高浓度PHMB治疗深层基质浸润的潜在获益,在治疗试验中使用0.08% PHMB具有合理性。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照试验,纳入90名健康志愿者。
  • 受试者接受0.04%、0.06%、0.08% PHMB或安慰剂(溶媒)滴眼,每日12次共7天,随后每日6次共7天。

主要发现

  • 90名受试者中5例在开始治疗后1-4天内出现剂量限制性不良事件,其中2例使用0.06% PHMB,3例使用0.08% PHMB,均在1-15天内缓解。
  • 各治疗组间剂量限制性不良事件发生率无显著差异。
  • 48/90名受试者(包括安慰剂组)出现轻度不良事件。
  • 除0.08% PHMB组角膜点状着色外,未观察到任何不良事件发生率随PHMB浓度增加而升高的趋势;该角膜点状着色在7-14天内完全消退。

关键数值与推荐

  • 主要结局为治疗组间剂量限制性不良事件发生率的差异。
  • 剂量限制性不良事件定义为导致中断给药的不良事件。

临床怎么用

  • 0.02% PHMB使用者可基于本研究结果获得安全性 reassurance。
  • 对于棘阿米巴角膜炎深层基质浸润,可考虑在治疗试验中使用0.08% PHMB。

局限性

  • 研究在健康成人志愿者中进行,其对不良事件的易感性可能低于棘阿米巴角膜炎受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Polyhexamethyl biguanide (PHMB), a widely used topical treatment for Acanthamoeba keratitis (AK), is unlicensed with no formal safety assessment. This study evaluated its safety and tolerability. METHODS: A prospective, randomised, double-masked controlled trial in 90 healthy volunteers. Subjects were treated with topical 0.04%, 0.06%, 0.08% PHMB or placebo (vehicle) 12× daily for 7 days, then 6× daily for 7 days. The rates of dose-limiting adverse events (DLAEs) leading to interruption of dosing, mild adverse events (AEs) (not dose limiting) and incidental AEs (unrelated to treatment) were compared. The primary outcome was the difference between treatments for DLAE rates. RESULTS: 5/90 subjects developed DLAE within <1-4 days of starting treatment; 2/5 using PHMB 0.06% and 3/5 PHMB 0.08%. These resolved within 1-15 days. There were no significant differences in DLAE between treatment groups. Mild AEs occurred in 48/90 subjects (including placebo). There was no trend for an increased incidence of any AE with increasing concentrations of PHMB, except for corneal punctate keratopathy with PHMB 0.08%, which fully resolved within 7-14 days. CONCLUSION: These findings are reassuring for PHMB 0.02% users. They also suggest that higher PHMB concentrations may show acceptable levels of tolerance and toxicity in AK subjects, whose susceptibility to AE may be greater than for the normal eyes in this study. Given the potential benefits of higher PHMB concentrations for treating deep stromal invasion in AK, we think that the use of PHMB 0.08% is justified in treatment trials. TRIAL REGISTRATION NUMBER: NCT02506257.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Papa V, van der Meulen I, Rottey S, et al. Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers. Br J Ophthalmol. 2020. PMID: 33239413. doi:10.1136/bjophthalmol-2020-317848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。